Patients with HER2-low disease had similar PFS when compared to patients with HER2-zero BC (median PFS: 25.2 vs 22.6 months; HR 0.99, 95% CI: 0.64–1.53, p = 0.972). Here, ERBB2 is linked to breast cancer.